MSHLTrastuzumab deruxtecan (Enhertu) Powder For Concentrate For Solution For Infusion 100 mg
1) Treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.
2) Treatment of HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have received two or more prior regimens, including a trastuzumab-based regimen.